Ann Dermatol.  2012 May;24(2):233-234.

Etanercept in the Treatment of Generalized Annular Pustular Psoriasis

• Lo Schiavo A
• Brancaccio G
• Puca RV
• Caccavale

Abstract

No abstract available.

MeSH Terms

Immunoglobulin G
Psoriasis
Receptors, Tumor Necrosis Factor
Etanercept
Immunoglobulin G
Receptors, Tumor Necrosis Factor

Figure

• 

  Fig. 1 Clinical presentation on admission.

• 

  Fig. 2 Complete clearance of the pustular eruption after etanercept treatment.

Reference

1. Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J Dermatol. 1997. 36:266–271.

2. Bazex A, Dupré A, Chiristol B, Jalby J. Psoriasis with recurrent circinate erythema of the Bloch type. Bull Soc Fr Dermatol Syphiligr. 1967. 74:689–695.

3. Lapiere S. Deux cas de psoriasis recidivant a elements evoluant de facon anormalement rapide en quelques jours. Arch Belg Derm. 1959. 15:7–12.

4. Vieira Serrão V, Martins A, Lopes MJ. Infliximab in recalcitrant generalized pustular arthropatic psoriasis. Eur J Dermatol. 2008. 18:71–73.

5. Esposito M, Mazzotta A, Casciello C, Chimenti S. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Dermatology. 2008. 216:355–360.

6. Daudén E, Santiago-et-Sánchez-Mateos D, Sotomayor-López E, García-Díez A. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol. 2010. 163:1346–1347.

7. Weisenseel P, Prinz JC. Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis. 2006. 78:197–199.